Expert Video - How does my MDS genetic mutation permit personalized treatment decisions?

Rafael Bejar, MD, PhD, Director of the MDS Center of Excellence at the Moores Cancer Center of the University of San Diego, explains how testing for genetic mutations and chromosomal abnormalities can help your doctor personalize your MDS therapy. For example, risk-based therapy based on a 5q deletion can lead to therapy with lenalidomide and mutations on the IDH genes can lead to treatment with specific chemotherapy drugs.

  • Share with family and friends:

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.


This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.

This activity is supported by an educational grant from Acceleron Pharma, Bristol-Myers Squibb, Celgene Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals, and Takeda Oncology.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.